<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4444">
  <stage>Registered</stage>
  <submitdate>17/05/2014</submitdate>
  <approvaldate>17/05/2014</approvaldate>
  <nctid>NCT02143349</nctid>
  <trial_identification>
    <studytitle>The Effect of Coleus Forskohlii Extract on the Risk Factors of Metabolic Syndrome</studytitle>
    <scientifictitle>Investigation of Appetite Suppressant Properties Associated With Coleus Forskohlii in Overweight and Obese Individuals</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ACTRN12614000305628</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metabolic Syndrome</healthcondition>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Coleus forskohlii extract
Other interventions - Placebo

Experimental: Coleus forskohlii extract - Ingestion of 250 mg capsle (Coleus forskohlii extract) twice a day for 12 weeks

Placebo Comparator: Placebo - Ingestion of 250 mg capsule (placebo) twice a day for 12 weeks


Other interventions: Coleus forskohlii extract
Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks

Other interventions: Placebo
Ingestion of 250 mg placebo capsule twice a day for 12 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>changes in appetite will be assessed using visual analogue scale; blood hormone levels will also be measured using commercial kits.</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>reduction in central obesity - waist circumference will be measured on fortnight basis</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Both Australian males and females, age 20-60 years, Overweight or obese (BMI &gt;25),
             waist circumference of &gt; 94 cm (male), waist circumference of &gt;80 cm (female)</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Cigarette smoker, hypertension, all types of heart, liver and kidney disease,
             pregnancy, lactating, Type 1 diabetes and weight loss medication.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2015</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>College of Health and Biomedicine Victoria University - St. Albans</hospital>
    <postcode>14428 - St. Albans</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Olive Lifesciences Pvt Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>College of Health and Biomedicine, Victoria University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Coleus forskohlii extract contains the bioactive compound, forskolin. Preliminary studies
      have shown that forskolin can increase fat metabolism thus reduce fat accumulation in both
      animals and humans. It has been suggested that forskolin may also suppress appetite thus
      reduce energy intake and results in weight loss. This study will evaluate the appetite
      suppressant properties of Coleus forskohlii extract. In addition the effect on central
      obesity and risk factors of metabolic syndrome will also be investigated.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02143349</trialwebsite>
    <publication>obesity
Shivaprasad HN, Gopalakrishna S, Mariyanna B, Thekkoot M, Reddy R, Tippeswamy BS. Effect of Coleus forskohlii extract on cafeteria diet-induced obesity in rats. Pharmacognosy Res. 2014 Jan;6(1):42-5. doi: 10.4103/0974-8490.122916.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Xiao Su</name>
      <address />
      <phone>+61399192318</phone>
      <fax />
      <email>xiao.su@vu.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>